| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/28/2009 | WO2009045735A3 Method for stabilizing quercetin |
| 05/28/2009 | WO2009045700A3 5-lipoxygenase-activating protein (flap) inhibitors |
| 05/28/2009 | WO2009045313A3 Oxypiperidine derivatives as histamine receptor antagonists |
| 05/28/2009 | WO2009045083A3 Combination therapy for neuroprotection |
| 05/28/2009 | WO2009043320A3 Substituted 6-(alkylbenzylamino)purine derivatives for use as cytokinin receptor antagonists and preparations containing these derivatives |
| 05/28/2009 | WO2009040819A3 DOWN-REGULATION OF MORTALIN BY siRNA |
| 05/28/2009 | WO2009040671A4 Novel therapeutic uses of adrenergic alpha-1 receptor antagonists |
| 05/28/2009 | WO2009038757A3 Solid forms comprising n-(5-tert-butyl-isoxazol-3-yl)-n'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, compositions thereof, and uses therewith |
| 05/28/2009 | WO2009036933A9 Down regulation of the gene expression by means of nucleic acid-loaded virus-like particles |
| 05/28/2009 | WO2009029384A3 Compounds for the treatment of hepatitis c |
| 05/28/2009 | WO2009027482A3 Tsh receptor antagonizing tetrahydroquinoline compounds |
| 05/28/2009 | WO2009027346A3 17beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of hormone-dependent diseases |
| 05/28/2009 | WO2009027105A3 Method of providing patient specific immune response in amyloidoses and protein aggregation disorders |
| 05/28/2009 | WO2009026657A8 Flavonoid ppar agonists |
| 05/28/2009 | WO2009026517A3 Therapy for complications of diabetes |
| 05/28/2009 | WO2009024324A9 Treatment of sleep disorders |
| 05/28/2009 | WO2009019607A4 Beta adrenergic receptor ligand derivatives for modulating apoptosis |
| 05/28/2009 | WO2009016608A3 Pharmaceutical compositions of fenofibrate |
| 05/28/2009 | WO2009015734A3 Dosage form comprising immediate release naproxen and sustained release opioid analgesic |
| 05/28/2009 | WO2009014559A3 Heparosan-based biomaterials and coatings and methods of production and use thereof |
| 05/28/2009 | WO2009013010A3 5ht6-ligands such as sulfonamide derivatives in drug- induced weight-gain |
| 05/28/2009 | WO2008156610A3 Antibiotic compounds |
| 05/28/2009 | WO2008152131A3 Rnai inhibition of alpha-enac expression |
| 05/28/2009 | WO2008152086A3 4,5-dihydro-(1h)-pyrazole derivatives as cannabinoid cb1 receptor modulators |
| 05/28/2009 | WO2008152081A3 Anthelmintic benzo[d]isoxazolyl benzamide derivatives |
| 05/28/2009 | WO2008143730A3 Macrolide compounds and methods of making and using the same |
| 05/28/2009 | WO2008138327A3 Polymerase inhibitors and the use thereof for the treatment of tumors |
| 05/28/2009 | WO2008127290A3 Alginate and alginate lyase compositions and methods of use |
| 05/28/2009 | WO2008125633A3 Egfr inhibitors for treatment and diagnosis of metastatic prostate cancer |
| 05/28/2009 | WO2008112162A3 Compositions and methods for treating diseases, disorders or conditions characterized by myelin degeneration, myelin deficiency or loss |
| 05/28/2009 | WO2008071960A3 Methods of increasing neurogenesis |
| 05/28/2009 | WO2008068615A8 Crystalline forms of ( 3 s ) -3- [n- (n' - (2-tert-butylphenyl) oxamyl) alaninyl] amino-5- (2 ', 3 ', 5 ', 6 ' -tetrafluoro phenoxy) -4-0x0penta noic acid |
| 05/28/2009 | WO2008032164A3 Benzimidazolone derivatives |
| 05/28/2009 | WO2008020453A3 A process for the preparation of a novel crystalline polymorph of aripiprazole |
| 05/28/2009 | WO2007106633A3 Perfluorochemical treatment process and apparatus |
| 05/28/2009 | WO2007050383A3 Tyrosine kinase inhibitors |
| 05/28/2009 | WO2007044727A3 Pkr activation via hybridization chain reaction |
| 05/28/2009 | WO2006073922A3 Package for cyanoacrylate adhesive |
| 05/28/2009 | WO2006036956A3 Therapeutic regimen for treating cancer using quassinoids and other chemotherapeutic agents |
| 05/28/2009 | WO2005030927A3 Methods and compositions for in vivo inflammation monitoring |
| 05/28/2009 | US20090138978 Use of bridge-1 and activators and inhibitors thereof in the treatment of insulin deficiency and diabetes |
| 05/28/2009 | US20090138076 Medical devices for delivery of therapeutic agents |
| 05/28/2009 | US20090137981 Methods of treating a blood vessel |
| 05/28/2009 | US20090137845 Novel 4-Dedimethylaminotetracycline derivatives |
| 05/28/2009 | US20090137834 Levodopa prodrugs, and compositions and uses thereof |
| 05/28/2009 | US20090137806 Dual nk1/nk3 receptor antagonists |
| 05/28/2009 | US20090137805 N-phenyl-2-pyrimidine-amine derivatives |
| 05/28/2009 | US20090137804 Compounds and Compositions as Protein Kinase Inhibitors |
| 05/28/2009 | US20090137801 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
| 05/28/2009 | US20090137778 A HIV peptide consisting of 23 to 50 amino acid residues; trans-activator |
| 05/28/2009 | US20090137687 Compositions and Methods With Enhanced Therapeutic Activity |
| 05/28/2009 | US20090137686 Treatment of Ophthalmic Diseases |
| 05/28/2009 | US20090137685 Therapeutic Agent for Inflammatory Bowel Disease Containing as Active Ingredient 2-Amino-1,3-Propanediol Derivative, or Method for Treating Inflammatory Bowel Disease |
| 05/28/2009 | US20090137684 Sustained-release preparations and method for producing the same |
| 05/28/2009 | US20090137683 Anticancer effect enhancer |
| 05/28/2009 | US20090137682 Combination cancer therapy with bis(thiohydrazide) amide compounds |
| 05/28/2009 | US20090137681 Sirtuin Inhibiting Compounds |
| 05/28/2009 | US20090137680 Novel non-selective cation channel in neuronal cells and method for treating brain swelling |
| 05/28/2009 | US20090137679 ZN2+Chelating Motif-Tethered Short-Chain Fatty Acids as a Novel Class of Histone Deacetylase Inhibitors |
| 05/28/2009 | US20090137678 High yield synthesis methods for producing organic salts of strontium |
| 05/28/2009 | US20090137677 Abuse-resistant amphetamine prodrugs |
| 05/28/2009 | US20090137676 Abuse-resistant amphetamine prodrugs |
| 05/28/2009 | US20090137675 Abuse-resistant amphetamine prodrugs |
| 05/28/2009 | US20090137674 Administering L-lysine-d-amphetamine or salts |
| 05/28/2009 | US20090137673 Abuse-resistant amphetamine prodrugs |
| 05/28/2009 | US20090137672 Abuse-resistant amphetamine prodrugs |
| 05/28/2009 | US20090137671 Methods of treating metabolic disorders |
| 05/28/2009 | US20090137670 Amino Acid Compounds |
| 05/28/2009 | US20090137669 Creatine ester anti-inflammatory compounds and formulations |
| 05/28/2009 | US20090137668 1-Acetoxy-1-nitrosocyclohexane; congestive heart failure; used with non-steroidal anti-inflammatory drug (NSAID); treating gastrointestinal side effects associated with NSAID |
| 05/28/2009 | US20090137666 FLUORESCENT PARTICLES COMPRISING NANOSCALE ZnO LAYER AND EXHIBITING CELL-SPECIFIC TOXICITY |
| 05/28/2009 | US20090137665 Novel method of neuroprotection by pharmacological inhibition of amp-activated protein kinase |
| 05/28/2009 | US20090137664 Saururus cernuus compounds that inhibit cellular responses to hypoxia |
| 05/28/2009 | US20090137663 Therapeutic micro nutrient composition for drug delivery |
| 05/28/2009 | US20090137662 Synergy of dopamine d2 and adenosine a2 receptors activates pka signaling via beta/gamma dimers |
| 05/28/2009 | US20090137661 Plant derived compounds and compound formulae containing the same for the treatment of cervical cancer |
| 05/28/2009 | US20090137660 Cytokine Modulators Using Cyclic Glycerides of Essential Polyunsaturated Fatty Acids |
| 05/28/2009 | US20090137659 Compounds that modulate intracellular calcium |
| 05/28/2009 | US20090137658 Benzenesulfonic acid salt compounds |
| 05/28/2009 | US20090137657 External liquid preparation containing indomethacin |
| 05/28/2009 | US20090137656 Intermolecular Association Complex of a Carrier and of an Active Principle |
| 05/28/2009 | US20090137655 Non-Steroidal Ligands for the Glucocorticoid Receptor, Compositions and Uses Thereof |
| 05/28/2009 | US20090137654 Methods of modulating binding of son of sevenless to phosphatidic acid and identifying compounds that modulate such binding |
| 05/28/2009 | US20090137653 Substituted benzylamines as cyp2a inhibitors and uses thereof to treat nicotine dependence |
| 05/28/2009 | US20090137652 Methods for neuroprotection |
| 05/28/2009 | US20090137651 Pharmaceutical composition for external use |
| 05/28/2009 | US20090137650 New Compounds |
| 05/28/2009 | US20090137648 Process for the preparation of irbesartan hydrochloride |
| 05/28/2009 | US20090137647 Modified Macrophage Migration Inhibitory Factor Inhibitors |
| 05/28/2009 | US20090137645 Shelf-Stable Famotidine Granulates for Oral Suspensions |
| 05/28/2009 | US20090137644 Rhodanine compositions for use as antiviral agents |
| 05/28/2009 | US20090137643 Methods for Inhibiting or Reversing Tau Filament Fibrillization |
| 05/28/2009 | US20090137642 2-Acylaminothiazole Derivatives |
| 05/28/2009 | US20090137641 Potassium Channel Activators for the Prevention and Treatment of Dystonia and Dystonia-Like Symptoms |
| 05/28/2009 | US20090137640 Potentiator for radiation therapy comprising pyridine derivative as active ingredient |
| 05/28/2009 | US20090137639 Methods for controlling fungi and bacteria |
| 05/28/2009 | US20090137638 Thiazolidinedione analogues |
| 05/28/2009 | US20090137637 Tetrazolyl-Methylene Amino Acid Derivatives |
| 05/28/2009 | US20090137636 Reverse Isoxazoles |
| 05/28/2009 | US20090137635 Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators |